The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Thalidomide Suppresses NF-κB Activation Induced by TNF and H2O2, But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester
Abstract
Thalidomide ([+]-α-phthalimidoglutarimide), a psychoactive drug that readily crosses the blood-brain barrier, has been shown to exhibit anti-inflammatory, antiangiogenic, and immunosuppressive properties through a mechanism that is not fully established. Due to the central role of NF-κB in these responses, we postulated that thalidomide mediates its effects through suppression of NF-κB activation. We investigated the effects of thalidomide on NF-κB activation induced by various inflammatory agents in Jurkat cells. The treatment of these cells with thalidomide suppressed TNF-induced NF-κB activation, with optimum effect occurring at 50 μg/ml thalidomide. These effects were not restricted to T cells, as other hematopoietic and epithelial cell types were also inhibited. Thalidomide suppressed H2O2-induced NF-κB activation but had no effect on NF-κB activation induced by PMA, LPS, okadaic acid, or ceramide, suggesting selectivity in suppression of NF-κB. The suppression of TNF-induced NF-κB activation by thalidomide correlated with partial inhibition of TNF-induced degradation of an inhibitory subunit of NF-κB (IκBα), abrogation of IκBα kinase activation, and inhibition of NF-κB-dependent reporter gene expression. Thalidomide abolished the NF-κB-dependent reporter gene expression activated by overexpression of TNFR1, TNFR-associated factor-2, and NF-κB-inducing kinase, but not that activated by the p65 subunit of NF-κB. Overall, our results clearly demonstrate that thalidomide suppresses NF-κB activation specifically induced by TNF and H2O2 and that this may contribute to its role in suppression of proliferation, inflammation, angiogenesis, and the immune system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
Parman, T., Wiley, M. J., & Wells, P. G. (1999) · Nature Medicine · doi:10.1038/8466 · Cited by 495
Cited by
The IKK NF-κB system: a treasure trove for drug development
Karin, M., Yamamoto, Y., & Wang, Q. M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1279 · Cited by 1,364
Aggarwal, B. B., Vijayalekshmi, R. V., & Sung, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0149 · Cited by 795
Self-citationSedger, L. M., & McDermott, M. F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.016 · Cited by 771
GLIA: A novel drug discovery target for clinical pain
Watkins, L. R., & Maier, S. F. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1251 · Cited by 672
Franks, M. E., Macpherson, G. R., & Figg, W. D. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16308-3 · Cited by 615
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
TNF: A master switch for inflammation to cancer
Sethi, G. (2008) · Frontiers in Bioscience · doi:10.2741/3066 · Cited by 458
Nuclear factor-kappa B signaling in skeletal muscle atrophy
Li, H., Malhotra, S., & Kumar, A. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0373-8 · Cited by 441
Transcription Factor NF‐κB: A Sensor for Smoke and Stress Signals
AHN, K. S., & AGGARWAL, B. B. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1352.026 · Cited by 432
Self-citationBhardwaj, A., Sethi, G., Vadhan-Raj, Bueso-Ramos, C., Takada, Y., Gaur, U., Nair, A. S., Shishodia, S., & Aggarwal, B. B. (2007) · Blood · doi:10.1182/blood-2006-02-003988 · Cited by 395
Self-citationThe role of NF-κB in the regulation of cell stress responses
Wang, T., Zhang, X., & Li, J. J. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00058-9 · Cited by 343
Cancer drug discovery by repurposing: teaching new tricks to old dogs
Gupta, S. C., Sung, B., Prasad, S., Webb, L. J., & Aggarwal, B. B. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.06.005 · Cited by 340
Self-citationBharti, A. C., Shishodia, S., Reuben, J. M., Weber, D., Alexanian, R., Raj-Vadhan, S., Estrov, Z., Talpaz, M., & Aggarwal, B. B. (2004) · Blood · doi:10.1182/blood-2003-06-2151 · Cited by 318
Self-citationLappas, C. M., Day, Y.-J., Marshall, M. A., Engelhard, V. H., & Linden, J. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061097 · Cited by 295
Shishodia, S., Potdar, P., Gairola, C. G., & Aggarwal, B. B. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg078 · Cited by 292
Self-citationMalik, F., Kumar, A., Bhushan, S., Khan, S., Bhatia, A., Suri, K. A., Qazi, G. N., & Singh, J. (2007) · Apoptosis · doi:10.1007/s10495-007-0129-x · Cited by 254
Metadata
- Authors
- Majumdar, S., Lamothe, B., & Aggarwal, B. B.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-03
- Volume
- 168
- Issue
- 6
- Pages
- 2644-2651
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2079190230
- Cited by
- 160
- References
- 2
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.